Literature DB >> 18351522

Amyotrophic lateral sclerosis from bench to bedside.

Catherine Lomen-Hoerth1.   

Abstract

Amyotrophic lateral sclerosis (ALS) is a progressive disease for which there are currently no significant treatments to alter the fatal outcome. The cause of the disease is still elusive, except in familial cases where significant advances have been made in identifying new genetic causes. ALS is a relatively rare disease affecting approximately 1 in 100,000 people equally across geographic and ethnic distributions. It is a difficult disease to diagnose, and there are many mimics of ALS. Overlap with dementia may provide new clues to the etiology and treatment. There have been many advances in symptomatic treatments and improvements in the quality of life for ALS patients due to technological advancements.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18351522     DOI: 10.1055/s-2008-1062265

Source DB:  PubMed          Journal:  Semin Neurol        ISSN: 0271-8235            Impact factor:   3.420


  13 in total

1.  Amyotrophic lateral sclerosis: clinical management and research update.

Authors:  Jinsy Andrews
Journal:  Curr Neurol Neurosci Rep       Date:  2009-01       Impact factor: 5.081

Review 2.  Interplay Between Exosomes, microRNAs and Toll-Like Receptors in Brain Disorders.

Authors:  Vera Paschon; Silvia Honda Takada; Juliane Midori Ikebara; Erica Sousa; Reza Raeisossadati; Henning Ulrich; Alexandre Hiroaki Kihara
Journal:  Mol Neurobiol       Date:  2015-04-11       Impact factor: 5.590

Review 3.  Frontotemporal lobar degeneration: epidemiology, pathophysiology, diagnosis and management.

Authors:  Gil D Rabinovici; Bruce L Miller
Journal:  CNS Drugs       Date:  2010-05       Impact factor: 5.749

4.  Amyotrophic lateral sclerosis: update and new developments.

Authors:  Ashley J Pratt; Elizabeth D Getzoff; J Jefferson P Perry
Journal:  Degener Neurol Neuromuscul Dis       Date:  2012-02

Review 5.  Toll-like receptors expression and signaling in glia cells in neuro-amyloidogenic diseases: towards future therapeutic application.

Authors:  Dorit Trudler; Dorit Farfara; Dan Frenkel
Journal:  Mediators Inflamm       Date:  2010-07-25       Impact factor: 4.711

6.  Extracellular mutant SOD1 induces microglial-mediated motoneuron injury.

Authors:  Weihua Zhao; David R Beers; Jenny S Henkel; Wei Zhang; Makoto Urushitani; Jean-Pierre Julien; Stanley H Appel
Journal:  Glia       Date:  2010-01-15       Impact factor: 7.452

7.  Detection of endothelial cell-associated human DNA reveals transplanted human bone marrow stem cell engraftment into CNS capillaries of ALS mice.

Authors:  Svitlana Garbuzova-Davis; Kayla J Boccio; Jared Ehrhart; Paul R Sanberg; Stanley H Appel; Cesario V Borlongan
Journal:  Brain Res Bull       Date:  2021-02-02       Impact factor: 4.077

8.  Adenylyl cyclase type 3, a marker of primary cilia, is reduced in primary cell culture and in lumbar spinal cord in situ in G93A SOD1 mice.

Authors:  Xiaoxing Ma; Randy Peterson; John Turnbull
Journal:  BMC Neurosci       Date:  2011-07-18       Impact factor: 3.288

Review 9.  Drosophila melanogaster as a model organism of brain diseases.

Authors:  Astrid Jeibmann; Werner Paulus
Journal:  Int J Mol Sci       Date:  2009-02-02       Impact factor: 6.208

10.  Methylene blue protects against TDP-43 and FUS neuronal toxicity in C. elegans and D. rerio.

Authors:  Alexandra Vaccaro; Shunmoogum A Patten; Sorana Ciura; Claudia Maios; Martine Therrien; Pierre Drapeau; Edor Kabashi; J Alex Parker
Journal:  PLoS One       Date:  2012-07-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.